臺灣博碩士論文加值系統

根據中華民國行政院衛生署國民健康局所發布九十六年癌症登記報告指出，口腔癌目前已成為台灣男性十大癌症中新增率最高的癌症，平均死亡年齡五十四歲，堪稱男性青壯年殺手。口腔癌的治療常造成巨大的顏面外觀損害及飲食機能改變，五年存活率整體也僅有五成五左右，末期(第四期)病患存活率更是減至四成以下。口腔癌常常會發生第二原發性腫瘤，因此，雖然目前的手術方式、放射線及化學治療都較從前有長足的進步，其生存率仍沒有重大起色。因此能夠在癌症早期甚至是尚未產生癌症時就予以預防及抑制產生，是一個相當值得研究的課題。

化學預防(chemoprevention)的概念是在一九七六年由Sporn所提出，利用一些自然或是合成的特定製劑對於侵襲性癌症有回復、抑制或是防止惡化的效果。已有許多研究證實非類固醇抗發炎類藥物(non-steroidal anti-inflammatory drugs, NSAIDs)可以透過抑制環氧化酵素二型(cyclooxygenase-2, COX-2)來預防大腸直腸癌。考慮到大腸直腸癌的成因與口腔癌有許多相似之處，因此我們也對於NASIDs類藥物是否也可以在口腔組織有相同的功效特別有興趣。

我們遵循既有的診斷模式，先以病變處組織切片的病理診斷，初步篩選出有口腔癌前病變之受試者，再經由所訂定的受試者納入條件，選出符合條件的最後受試者。服用三個月的希樂葆(CELEBREX®)後，觀察其癌前病灶之變化，並再次於病灶處進行切片手術。然後就其臨床診斷、化學預防前後組織切片之病理診斷、免疫組織化學染色結果及病患本身之嚼食檳榔、抽菸及飲酒習慣等資料做比較，期待能找出以COX-2選擇性抑制劑做為化學預防的效果及角色。

結果發現，三個月的化學預防後，病灶處無明顯之改變，病理診斷也無顯著差異。不過可以發現，組織中COX-2表現明顯地下降，而且與細胞增殖有關的Ki-67之表現有正相關性，但與細胞凋亡相關的Bcl-2與Survivin無關聯性。我們也發現，抽菸、喝酒及嚼食檳榔等習慣都對於COX-2抑制劑的抑制效果都有所影響。三個月的化學預防期間，受試者皆沒有出現任何心血管方面的副作用，也沒有嚴重的身體不適情況。受試者在經過第二次切片手術後，繼續接受常規的治療，追蹤觀察至今，有超過半數以上的受試者已達到完全反應(complete response, CR)，並且無復發的跡象。

三個月的化學預防療程，對於原先病灶處的減小及消除是無效的，但在組織中的確可以發現COX-2表現減少的情況，因此原病灶後續的進展以及日後他處是否有癌前病變出現的情況，仍具有相當的研究價值。COX-2被抑制後，對於細胞增殖的路徑有所影響，但是對於細胞凋亡路徑的影響性還需要再確認。另外，不良口腔習慣的確會對於COX-2的抑制效果產生影響，因此，當大部分受試者仍持續有這些習慣時，對於短期內化學預防效果的研判是有影響的。我們認為COX-2化學預防應有其價值功效，但仍須有更大規模、更多控制變因且更嚴謹的研究設計來探討其角色與價值。

In Taiwan, especially due to the habit of betel quid chewing, the annual incidence of oral cancer is more than 4,000 cases. This disease combines with severe morbidity, which results in the 5-year survival rate is about 55% only. Oral cancer is frequently preceded by multifocal oral potentially malignant disorders (PMD) during multistep carcinogenesis, but there is still no better approach proved to be able to attenuate the occurring of oral cancer by the turnover of oral PMD.

Cyclooxygenase-2 (COX-2) is induced by many factors including inflammatory stimuli, growth factors, tumor promoters, oncogenes, and carcinogens. Overexpression of COX-2, therefore, will inhibit many reactions like apoptosis, and increase cell proliferation, promote angiogenesis, or suppress immune surveillance, thus encourages the accumulation of genetic damage in epithelial cells. Previous in vitro and in vivo studies showed that COX-2 is overexpressed in oral PMD and head and neck squamous cell carcinoma, those results led us to hypothesize that inhibiting COX-2 in premalignant tissue would be an effective chemopreventive strategy for patients with oral PMD. In order to investigate the hypothesis, we go on this study.

In our study, 26 participants were recruited to give celecoxib, 400mg twice daily, for 12weeks. Biopsies were applied at baseline day and week 12. All participants enrolled in the study were required to have at least one pathologically proved oral PMD (hyperkeratosis, mild dysplasia and moderate dysplasia). After that, we evaluated the efficacy, safety and influences of celecoxib in patients with oral PMD. We also compared the effect of oral habits (betel quid chewing, cigarette smoking and alcohol drinking) with the efficacy of chemoprevention.

After 12-week chemoprevention, there were no significant differences in many characters including the size, the thickness, the color and the texture of the lesions, and there were also no obvious changes in pathological diagnosis. But we found COX-2 expression was significantly decreased and Ki-67 expression was positively correlated with COX-2 expression, however, there was no correlation in the expression of Survivin and Bcl-2 compared with COX-2. We also found that cigarette smoking, alcohol drinking and betel quid chewing were impacts for inhibition of COX-2 expression. In the periods of this study, participants had no cardiovascular side effects or serious illness situation. After the second biopsy, participants whose lesions still existed continued to have further treatments (cryotherapy, photodynamic therapy or surgical excision) and to be follow up so far（about 2 years）, more than half of those participants’ diseases were completely healed without recurrence.

Three-month chemoprevention regimen for the remission or reduction of the oral precancerous lesion was ineffective. However, keeping follow-up the original lesion still had the considerable research value. COX-2 might affect cell proliferation, but the impact of the pathway of apoptosis by taking celecoxib still need to be confirmed. In addition, bad oral habits will indeed affect COX-2 inhibition and therefore, while most of the participants continued to have those habits, we couldn’t easily judge the efficacy of COX-2 chemoprevention. Our results showed that COX-2 chemoprevention should possess its own value, but it is necessary to have more rigorous studies to investigate the role and value of COX-2 chemoprevention.

口試委員會審定書 2
誌謝 3
中文摘要 4
英文摘要 6

第一章 序論
第一節 口腔癌前病變與鱗狀細胞癌之流行病學、診斷與治療 9
第二節 運用於口腔癌前病變與鱗狀細胞癌之化學預防 12
第三節 以非類固醇抗發炎類藥物作為化學預防之製劑 16
第四節 環氧化酵素二型抑制劑於癌前病變與鱗狀細胞癌之化學預防 18
第五節 希樂葆 (CELEBREX®)之介紹 21
第六節 研究目標 24

第二章 實驗材料與方法
第一節 受試者之選擇 25
第二節 篩選與註冊過程 26
第三節 治療計畫 27
第四節 免疫組織化學染色 28
第五節 統計學方法 29

第三章 實驗結果 31
第四章 討論 50
第五章 結論 60
第六章 未來展望 61
第七章 參考文獻 62
第八章 附件 78

1.中華民國行政院衛生署國民健康局, 中華民國96年癌症登記報告CANCER REGISTRY ANNUAL REPORT, 2007 TAIWAN 2010.
2.IARC, Betel-quid and areca nut chewing and some related nitrosamines. IARC Monogr Eval Carcinog Risks Hum, 2003. 85.
3.Ko, Y.C., et al., Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med, 1995. 24(10): p. 450-3.
4.國民健康局97年健康行為危險因子監測與成人吸菸行為調查. 2009; Available from: http://www.bhp.doh.gov.tw/BHPnet/Portal/PressShow.aspx?No=200906060001.
5.Oral Cancer. Available from: http://www.mskcc.org/mskcc/html/9983.cfm#400637.
6.Mirbod, S.M. and S.I. Ahing, Tobacco-associated lesions of the oral cavity: Part II. Malignant lesions. J Can Dent Assoc, 2000. 66(6): p. 308-11.
7.Diaz, E.M., Jr., et al., Squamous cell carcinoma of the buccal mucosa: one institution''s experience with 119 previously untreated patients. Head Neck, 2003. 25(4): p. 267-73.
8.La Vecchia, C., et al., Epidemiology and prevention of oral cancer. Oral Oncol, 1997. 33(5): p. 302-12.
9.Janakarajah, N. and R. Zain, Clinical presentation of buccal carcinoma. A review of twenty nine patients. Singapore Med J, 1984. 25(4): p. 236-9.
10.Chen, Y.K., et al., Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncol, 1999. 35(2): p. 173-9.
11.Hakama, M., Effect of population screening for carcinoma of the uterine cervix in Finland. Maturitas, 1985. 7(1): p. 3-10.
12.Shapiro, S., et al., Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst, 1982. 69(2): p. 349-55.
13.Alexander, F.E., et al., 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet, 1999. 353(9168): p. 1903-8.
14.Mandel, J.S., et al., Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst, 1999. 91(5): p. 434-7.
15.Kronborg, O., et al., Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet, 1996. 348(9040): p. 1467-71.
16.Sankaranarayanan, R., et al., Early findings from a community-based, cluster-randomized, controlled oral cancer screening trial in Kerala, India. The Trivandrum Oral Cancer Screening Study Group. Cancer, 2000. 88(3): p. 664-73.
17.Sankaranarayanan, R., et al., Visual inspection in oral cancer screening in Cuba: a case-control study. Oral Oncol, 2002. 38(2): p. 131-6.
18.Sankaranarayanan, R., et al., Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet, 2005. 365(9475): p. 1927-33.
19.WHO, Report of a meeting of investigators on the histological definition of precancerous lesions. Geneva: World Health Organization,, 1973. Can: p. 731.
20.Kramer, I.R., et al., Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol, 1978. 46(4): p. 518-39.
21.Warnakulasuriya, S., N.W. Johnson, and I. van der Waal, Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007. 36(10): p. 575-80.
22.Murti, P.R., et al., Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol, 1985. 13(6): p. 340-1.
23.Hsue, S.S., et al., Malignant transformation in 1458 patients with potentially malignant oral mucosal disorders: a follow-up study based in a Taiwanese hospital. J Oral Pathol Med, 2007. 36(1): p. 25-9.
24.Sudbo, J., et al., Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions.[retraction in Oral Oncol. 2007 Apr;43(4):420; PMID: 17457993]. Oral Oncology, 2003. 39(5): p. 497-505.
25.Zhang, L., et al., Impact of localized treatment in reducing risk of progression of low-grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol, 2001. 37(6): p. 505-12.
26.Sporn, M.B., et al., Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc, 1976. 35(6): p. 1332-8.
27.Fisher, B., et al., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 1998. 90(18): p. 1371-88.
28.Thun, M.J., M.M. Namboodiri, and C.W. Heath, Jr., Aspirin use and reduced risk of fatal colon cancer. N Engl J Med, 1991. 325(23): p. 1593-6.
29.Steinbach, G., et al., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 2000. 342(26): p. 1946-52.
30.Khuri, N.F.S.a.F.R., Chemoprevention in Head and Neck Cancer Current Clinical Oncology, ed. D.J. Adelstein. 2007: Humana Press. 279-303.
31.Dannenberg, A.J., et al., Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol, 2005. 23(2): p. 254-66.
32.Lippman, S.M., J. Sudbo, and W.K. Hong, Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol, 2005. 23(2): p. 346-56.
33.Mao, L., W.K. Hong, and V.A. Papadimitrakopoulou, Focus on head and neck cancer. Cancer Cell, 2004. 5(4): p. 311-6.
34.Hasegawa, M., et al., Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene, 2002. 21(27): p. 4231-6.
35.Herman, J.G. and S.B. Baylin, Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 2003. 349(21): p. 2042-54.
36.Sen, S., Aneuploidy and cancer. Curr Opin Oncol, 2000. 12(1): p. 82-8.
37.Brown, K.S. and M.A. Kane, Chemoprevention of squamous cell carcinoma of the oral cavity. Otolaryngol Clin North Am, 2006. 39(2): p. 349-63.
38.Silverman, S., Jr., M. Gorsky, and F. Lozada, Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer, 1984. 53(3): p. 563-8.
39.Lumerman, H., P. Freedman, and S. Kerpel, Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1995. 79(3): p. 321-9.
40.Schepman, K.P., et al., Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol, 1998. 34(4): p. 270-5.
41.Sudbo, J., et al., DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med, 2001. 344(17): p. 1270-8.
42.Pinholt, E.M., J. Rindum, and J.J. Pindborg, Oral cancer: a retrospective study of 100 Danish cases. Br J Oral Maxillofac Surg, 1997. 35(2): p. 77-80.
43.Sudbo, J., et al., The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med, 2004. 350(14): p. 1405-13.
44.Betz, C.S. and A. Leunig, [Potential and limitations of fluorescence diagnosis and photodynamic therapy. Part II: Photodynamic therapy]. HNO, 2004. 52(2): p. 175-192.
45.Chen, H.M., et al., Successful treatment of oral verrucous hyperplasia and oral leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med, 2005. 37(2): p. 114-22.
46.Slaughter, D.P., H.W. Southwick, and W. Smejkal, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 1953. 6(5): p. 963-8.
47.Hong, W.K., et al., 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med, 1986. 315(24): p. 1501-5.
48.Lippman, S.M., et al., Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med, 1993. 328(1): p. 15-20.
49.Khuri, F.R., et al., Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst, 2006. 98(7): p. 441-50.
50.Panje, W.R., Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol, 1981. 107(11): p. 658-63.
51.Dubois, R.N., et al., Cyclooxygenase in biology and disease. FASEB J, 1998. 12(12): p. 1063-73.
52.Herschman, H.R., W. Xie, and S. Reddy, Inflammation, reproduction, cancer and all that.... The regulation and role of the inducible prostaglandin synthase. Bioessays, 1995. 17(12): p. 1031-7.
53.Eberhart, C.E., et al., Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994. 107(4): p. 1183-8.
54.Waddell, W.R. and R.W. Loughry, Sulindac for polyposis of the colon. J Surg Oncol, 1983. 24(1): p. 83-7.
55.Thun, M.J., S.J. Henley, and C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst, 2002. 94(4): p. 252-66.
56.Paganini-Hill, A., Aspirin and colorectal cancer: the Leisure World cohort revisited. Prev Med, 1995. 24(2): p. 113-5.
57.Lodi, G., et al., Interventions for treating oral leukoplakia. Cochrane Database Syst Rev, 2006(4): p. CD001829.
58.Grosch, S., et al., Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, 2006. 98(11): p. 736-47.
59.Moraitis D, A.T., Weksler B, et al., Tobacco smoke induces cyclooxygenase-2 in epithelial cell lines derived from the human aerodigestive tract. Proc Am Assoc Cancer Res, 2002. 43.
60.Gross, N.D., et al., Levels of prostaglandin E metabolite, the major urinary metabolite of prostaglandin E2, are increased in smokers. Clin Cancer Res, 2005. 11(16): p. 6087-93.
61.Jeng, J.H., et al., Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis, 2000. 21(7): p. 1365-70.
62.Huang, P.L., C.W. Chi, and T.Y. Liu, Effects of Areca catechu L. containing procyanidins on cyclooxygenase-2 expression in vitro and in vivo. Food Chem Toxicol, 2010. 48(1): p. 306-13.
63.Tang, D.W., et al., Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma--evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J Oral Pathol Med, 2003. 32(9): p. 522-9.
64.Tsubouchi, Y., et al., Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res, 2000. 20(5A): p. 2867-72.
65.Chan, G., et al., Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res, 1999. 59(5): p. 991-4.
66.Wang, Z., R. Polavaram, and S.M. Shapshay, Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett, 2003. 198(1): p. 53-8.
67.Wang, Z., C.F. Fuentes, and S.M. Shapshay, Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope, 2002. 112(5): p. 839-43.
68.RTOG. RTOG 0226 - Prevention of Second Primary Tumor 2003; Available from: http://www.rtog.org/committees/minutes/headneck.html.
69.Yelland, M.J., et al., Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford), 2007. 46(1): p. 135-40.
70.Katzung, B.G., BASIC AND CLINICAL PHARMACOLOGY. 10TH EDIDITION ed: McGraw Hill.
71.Silverstein, F.E., et al., Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA, 2000. 284(10): p. 1247-55.
72.Bresalier, R.S., et al., Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 2005. 352(11): p. 1092-102.
73.Nussmeier, N.A., et al., Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med, 2005. 352(11): p. 1081-91.
74.Fitzgerald, G.A., Prostaglandins: modulators of inflammation and cardiovascular risk. J Clin Rheumatol, 2004. 10(3 Suppl): p. S12-7.
75.Solomon, S.D., et al., Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med, 2005. 352(11): p. 1071-80.
76.Bertagnolli, M.M., et al., Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med, 2006. 355(9): p. 873-84.
77.Arber, N., et al., Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med, 2006. 355(9): p. 885-95.
78.Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer''s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials, 2006. 1(7): p. e33.
79.Kimmel, S.E., et al., Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med, 2005. 142(3): p. 157-64.
80.Mukherjee, D., S.E. Nissen, and E.J. Topol, Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001. 286(8): p. 954-9.
81.Chen, L.C. and D.M. Ashcroft, Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther, 2006. 31(6): p. 565-76.
82.Lipsky, P.E., The clinical potential of cyclooxygenase-2-specific inhibitors. Am J Med, 1999. 106(5B): p. 51S-57S.
83.Subbaramaiah, K., et al., Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med, 1997. 216(2): p. 201-10.
84.Taketo, M.M., Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst, 1998. 90(21): p. 1609-20.
85.Taketo, M.M., Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst, 1998. 90(20): p. 1529-36.
86.Ziegler, J., Early trials probe COX-2 inhibitors'' cancer-fighting potential. J Natl Cancer Inst, 1999. 91(14): p. 1186-7.
87.Kulmacz, R.J. and W.E. Lands, Prostaglandin H synthase. Stoichiometry of heme cofactor. J Biol Chem, 1984. 259(10): p. 6358-63.
88.Funk, C.D., et al., Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J, 1991. 5(9): p. 2304-12.
89.Toyoshima, T., et al., Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer, 2002. 86(7): p. 1150-6.
90.Akita, Y., et al., Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. Br J Dermatol, 2004. 151(2): p. 472-80.
91.Banerjee, A.G., et al., Deregulated cyclooxygenase-2 expression in oral premalignant tissues. Mol Cancer Ther, 2002. 1(14): p. 1265-71.
92.Mestre, J.R., et al., Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci, 1999. 889: p. 62-71.
93.Mohan, S. and J.B. Epstein, Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol, 2003. 39(6): p. 537-46.
94.Moraitis, D., et al., Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res, 2005. 65(2): p. 664-70.
95.Renkonen, J., H. Wolff, and T. Paavonen, Expression of cyclo-oxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Arch, 2002. 440(6): p. 594-7.
96.Nishimura, G., et al., An experimental model of tumor dormancy therapy for advanced head and neck carcinoma. Jpn J Cancer Res, 2000. 91(11): p. 1199-203.
97.Sawaoka, H., et al., Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest, 1999. 79(12): p. 1469-77.
98.Lee, C.H., et al., The precancer risk of betel quid chewing, tobacco use and alcohol consumption in oral leukoplakia and oral submucous fibrosis in southern Taiwan. Br J Cancer, 2003. 88(3): p. 366-72.
99.Shiu, M.N., et al., Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer, 2000. 82(11): p. 1871-4.
100.Yang, Y.H., et al., Epidemiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan. J Oral Pathol Med, 2001. 30(4): p. 213-9.
101.Papadimitrakopoulou, V.A., et al., Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res, 2008. 14(7): p. 2095-101.
102.Papadimitrakopoulou, V.A., et al., Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res, 2008. 14(7): p. 2095-101.
103.Mulshine, J.L., et al., Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.[see comment]. Clinical Cancer Research, 2004. 10(5): p. 1565-73.
104.Wirth, L.J., et al., A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila Pa), 2008. 1(5): p. 339-48.
105.Baron, J.A., et al., A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 2006. 131(6): p. 1674-82.
106.McAdam, B.F., et al., Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A, 1999. 96(1): p. 272-7.
107.Bertagnolli, M.M., Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. The Lancet Oncology, 2007. 8(5): p. 439-443.
108.Shibata, M., et al., Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol, 2005. 41(3): p. 304-12.
109.Santhi, W.S., et al., NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. Exp Mol Pathol, 2006. 81(2): p. 123-30.
110.Warnakulasuriya, S., et al., Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med, 2008. 37(3): p. 127-33.
111.Scholzen, T. and J. Gerdes, The Ki-67 protein: from the known and the unknown. J Cell Physiol, 2000. 182(3): p. 311-22.
112.Duchrow, M., J. Gerdes, and C. Schluter, The proliferation-associated Ki-67 protein: definition in molecular terms. Cell Prolif, 1994. 27(5): p. 235-42.
113.Davies, L., N.J. Hardin, and B.G. Beatty, Can Ki-67 predict recurrence of NO squamous cell carcinoma of the tongue? Ann Otol Rhinol Laryngol, 2006. 115(1): p. 12-7.
114.Sittel, C., et al., Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol, 1999. 35(6): p. 583-9.
115.Kwong, R.A., et al., p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res, 2005. 11(11): p. 4107-16.
116.Kim, E.S., et al., Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila Pa), 2010. 3(2): p. 148-59.
117.Mao, J.T., et al., Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res, 2006. 12(1): p. 314-20.
118.Autret, A. and S.J. Martin, Emerging role for members of the Bcl-2 family in mitochondrial morphogenesis. Mol Cell, 2009. 36(3): p. 355-63.
119.Tsujimoto, Y., Bcl-2 family of proteins: life-or-death switch in mitochondria. Biosci Rep, 2002. 22(1): p. 47-58.
120.Jordan, R.C., et al., Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Eur J Cancer B Oral Oncol, 1996. 32B(6): p. 394-400.
121.Singh, B.B., et al., Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 1998. 85(6): p. 692-8.
122.Yao, L., M. Iwai, and I. Furuta, Correlations of bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol, 1999. 35(1): p. 56-62.
123.Schoelch, M.L., et al., Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol, 1999. 35(1): p. 77-85.
124.McAlinden, R.L., et al., Bcl-2 expression in sequential biopsies of potentially malignant oral mucosal lesions assessed by immunocytochemistry. Oral Dis, 2000. 6(5): p. 318-26.
125.Loro, L.L., A.C. Johannessen, and O.K. Vintermyr, Decreased expression of bcl-2 in moderate and severe oral epithelia dysplasias. Oral Oncol, 2002. 38(7): p. 691-8.
126.Du, Y., et al., Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1. Oncol Rep, 2008. 20(3): p. 605-11.
127.Ding, H., et al., Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer, 2005. 113(5): p. 803-10.
128.Jendrossek, V., R. Handrick, and C. Belka, Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J, 2003. 17(11): p. 1547-9.
129.LaCasse, E.C., et al., The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 1998. 17(25): p. 3247-59.
130.Altieri, D.C., Validating survivin as a cancer therapeutic target. Nat Rev Cancer, 2003. 3(1): p. 46-54.
131.Altieri, D.C., Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J Cell Biochem, 2004. 92(4): p. 656-63.
132.Altieri, D.C., Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, 2003. 22(53): p. 8581-9.
133.Monzo, M., et al., A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol, 1999. 17(7): p. 2100-4.
134.Lin, C.Y., et al., Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol, 2005. 41(6): p. 645-54.
135.Scheper, M.A., J.J. Sauk, and N.G. Nikitakis, COX-independent antineoplastic effects of sulindac in oral cancer are mediated by survivin down-regulation. Anticancer Res, 2006. 26(6B): p. 4103-13.
136.Ferrario, A., et al., Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res, 2002. 62(14): p. 3956-61.
137.Makowski, M., et al., Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res, 2003. 9(14): p. 5417-22.
138.Akita, Y., et al., Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity. British Journal of Dermatology, 2004. 151(2): p. 472-80.